World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
80271
World Ranking
16845
National Ranking
8443

Fred D. Lublin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Fred D. Lublin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 461 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Fred D. Lublin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Fred D. Lublin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Fred D. Lublin is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their primary research focuses on multiple sclerosis and related neurological disorders, with significant contributions to the understanding of disease mechanisms and clinical treatment outcomes.

The scientist's work spans a wide range of medical fields with a concentration in medicine, pathology and forensic medicine, neurology, rheumatology, molecular biology, and epidemiology. Their research topics prominently include multiple sclerosis research studies, peripheral neuropathies and disorders, rheumatoid arthritis research and therapies, polyomavirus and related diseases, SARS-CoV-2 and COVID-19 research, liver diseases and immunity, and autoimmune and inflammatory disorders research.

Recent publications by Fred D. Lublin highlight their involvement in multiple sclerosis research. Some notable papers are:

  • How patients with multiple sclerosis acquire disability, 2022, Brain
  • The 2013 clinical course descriptors for multiple sclerosis, 2020, Neurology

Though not a direct author on all recent influential papers in the field, they are associated with highly cited studies such as "Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study," published in 2021 in JAMA Neurology, demonstrating relevance in ongoing clinical trial research.

Fred D. Lublin frequently collaborates with other researchers in their field. Frequent co-authors include:

  • Gary Cutter
  • Sylvia Klineova
  • Bruce Cree
  • Stephen Krieger
  • Jerry S. Wolinsky

Publications are prominently featured in several scientific venues, including:

  • Neurology
  • Multiple Sclerosis and Related Disorders
  • Multiple Sclerosis Journal
  • The American Journal of Gastroenterology
  • Brain

Best Publications

  • Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

    Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet

  • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

    W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin

  • Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

    Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll

  • Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

    Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi

  • Defining the clinical course of multiple sclerosis Results of an international survey

    Fred D. Lublin;Stephen C. Reingold

  • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

    Chris H. Polman;Eva Havrdova;Michael Hutchinson;Ludwig Kappos

  • Defining the clinical course of multiple sclerosis: The 2013 revisions

    Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter

  • Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

    Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

    Richard A. Rudick;William H. Stuart;Peter A. Calabresi;Christian Confavreux

  • Development of a multiple sclerosis functional composite as a clinical trial outcome measure

    Gary R. Cutter;Monika L. Baier;Richard A. Rudick;Diane L. Cookfair

  • New multiple sclerosis phenotypic classification.

    Fred D. Lublin

  • Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

    D. S. Goodin;Elliot Frohman;G. P. Garmany;J. Halper

  • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery

  • Differential diagnosis of suspected multiple sclerosis: a consensus approach

    D. H. Miller;B. G. Weinshenker;M. Filippi;B. L. Banwell

  • Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

    Bruce A C Cree;Jeffrey L Bennett;Ho Jin Kim;Brian G Weinshenker

  • Effect of relapses on development of residual deficit in multiple sclerosis

    Fred D. Lublin;Monika Baier;Gary Cutter

  • Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

    D. H. Miller;P. S. Albert;F. Barkhof;G. Francis

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

    Richard Rudick;Jack Antel;Christian Confavreux;Gary Cutter

Frequent Co-Authors

Jerry S. Wolinsky
Jerry S. Wolinsky The University of Texas Health Science Center at Houston
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Chris H. Polman
Chris H. Polman VU University Medical Center
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Eva Havrdova
Eva Havrdova Charles University
Matilde Inglese
Matilde Inglese University of Genoa
Peter A. Calabresi
Peter A. Calabresi Johns Hopkins University School of Medicine
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Hans-Peter Hartung
Hans-Peter Hartung Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or supplemental degrees can open new doors in the medical field, even if you aren’t pursuing a traditional MD or DO in the USA. Many students consider online healthcare degrees for greater flexibility and faster career advancement. For instance, those interested in healthcare administration can benefit from choosing a cahme accredited online mha program, which ensures the degree meets rigorous quality standards and is respected by employers nationwide.

Registered nurses aiming to expand their qualifications often look for the best online rn to bsn programs without clinical requirements. These options allow nurses to balance work, family, and study while accelerating their academic progress. Similarly, those seeking leadership and advanced practice roles may choose accelerated msn to dnp programs to obtain the highest nursing credentials more quickly.

For professionals keen to avoid traditional clinical rotations, there are also online dnp programs without clinicals. These alternatives are ideal for nurses and administrators looking to upskill or move into advanced positions remotely, offering convenience without sacrificing educational quality.

Best Scientists Citing Fred D. Lublin

Trending Scientists

Recently Published Articles